|
1. Ling Yong#, Yan’e Liu#, Wei-zhe Jian, Lei Cai, Tian-yu Bao, Chen Liu, En-ze Gan, Tian-yu Wang, Ping-yao Luo, Bao-shan Cao*, Wei Liu*,
Tian-yan zhou*. Modeling exposure-driven drug-related adverse events in patients with non-small cell lung cancer treated with EGFR TKIs.
Acta Pharmacologica Sinica. Accepted.
2. Jingyi Yang, Qian Shen, Xiaoyan Ke, Wei Liu*, Ping Yang*. A case report of sustained cytokine release syndrome due to glofitamab and
literature review. Clinical Pharmacology: Advances and Applications. 2025, 17: 79-83.
3. Zhiheng Yu, Wei Liu#, Ziyu Wang, Yidong Chen, Jie Yan, Leslie Benet, and Suo-di Zhai. Is there a possibility that P-glycoprotein reduces
reproductive toxicity in males but breast cancer resistance protein does not? Clinical and Translational Science. 2024, 17(10):e70027.
4. Ping Yang#, Wei Liu#, Yingqiu Ying#, Libo Zhao#, Xin Xiong, Xianhua Zhang, Yinchu Cheng, Congya Zhou, Yuanyuan Zhang, Li Yang*,
Rongsheng Zhao*. Population Pharmacokinetics of Nirmatrelvir in Chinese Patients with COVID-19: Therapeutic Drug Monitoring and Dosing
Regimen Selection in Clinical Practice. International Journal of Antimicrobial Agents. 2024, Aug;64(2):107199.
5. Wei Liu#, Zhiyuan Tan#, Ping Yang#, Zhiheng Yu, Xueting Yao, Pengxiang Zhou, Ling Liu, Wei Zhou*. Model-based exploration of the rationality
of off-label use of cetirizine in Chinese pediatric patients: a prospective cohort study. Frontiers in Pharmacology. 2024, 10.3389/fphar.2024.1322788.
6. Wei Liu#, Ping Yang#, Ping Yang, Hongmei Jing, Li Yang, Libo Zhao*, Rongsheng Zhao*. Clinical characteristics and pharmacokinetics of
Paxlovid in hematological tumor patients. Medical Review. 2024, 4(2): 169-171.
7. Wei Liu#, Ziyang Wu#, Tong Sun#, Shuyao Liang#, Jun Zhu*, Suodi Zhai*. Management guidelines for preventing exposure to antineoplastics.
Chinese Journal of Cancer Research. 2023, 35(1): 1-10.
8. Wei Liu,Zhiheng Yu, Ziyu Wang, Suodi Zhai, Leslie Z. Benet*. Using an animal model to predict the effective human dose for oral multiple
sclerosis drugs. Clinical and Translational Science. 2023:16(3):467-477.
9. Xin Du#, Wei Liu#, Ken Chen, Ziyu Wang, Xinyi Li, Li Yang* and Xiaohui Xie*. Impact of Gastric-acid Suppressants Use on the Safety and
Effectiveness of EGFR-TKIs: A Systematic Review and Meta-analysis. Front. Pharmacol. 2022, 13: 796538.
10. Ziyu Wang, Xin Du, Ken Chen, Shanshan Li, Zhiheng Yu, Ziyang Wu, Li Yang, Dingding Chen*, Wei Liu*. Impact of dose reduction of afatinib
used in patients with non-small-cell lung cancer: A systematic review and meta-analysis. Front. Pharmacol. 2021, 12: 781084.
11. Xin Xiong, Yuanyuan Zhang, Ziyu Wang, Congya Zhou, Ping Yang, Xin Du, Li Yang, Wei Liu*. Simultaneous quantitative detection of afatinib,
erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid
chromatography-tandem mass spectrometry, Clinica Chimica Acta, 2022,527:1-10.
12. Na He, Fei Dong, Wei Liu*, Suodi Zhai*. A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia.
Infection and Drug Resistance. 2020:13, 1807-1821.
13. Wei Liu#, Pengxiang Zhou#, Ken Chen#, Zhikang Ye, Fang Liu, Xiaotong Li, Na He, Ziyang Wu, Qi Zhang, Xuepeng Gong, Qiyu Tang, Xin Du,
Yingqiu Ying, Xiaohan Xu, Yahui Zhang, Jinyu Liu, Yun Li, Ning Shen, Rachel J Couban, Quazi I Ibrahim, Gordon Guyatt, Suodi Zhai.
Efficacy and safety of antiviral treatment in COVID-19 based on evidence in SARS-CoV-2 and other acute viral infections:
systematic review and meta-analysis. Canadian Medical Association Journal. 2020, 192: E734-744.
14. Wei Liu#, Tingting Yan#, Ken Chen, Li Yang, Leslie Benet*, Suodi Zhai*. Predicting Interactions between Rifampin and Antihypertensive
Drugs Using the Biopharmaceutics Drug Disposition Classification System (BDDCS). Pharmacotherapy. 2020, 40(4):274-290.
15. 吴紫阳，何娜，程吟楚，翟所迪，刘维*. 基于美国FAERS数据库的恩美曲妥珠单抗和维布妥昔单抗的不良事件信号挖掘FAERS.
中国药房. 2022, 33(6): 740-744.
16. 韩晶，程吟楚，吴紫阳，杨璨羽，董菲，刘维*（共同通讯作者），翟所迪*. 右雷佐生在血液肿瘤患者使用的用药模式分析.
沈阳药科大学学报. 2022, 39(3): 333-338.
17. 刘维，母立峰，王紫愉，于之恒，翟所迪，曹宝山*. 程序性死亡受体-1及其配体单抗的不同给药方案的分析与比较.
临床药物治疗杂志. 2022, 20(2):1-7.
18. 刘维#, 薛钧升#,于之恒, 王紫愉, 陈镕, 周田彦*. 《基于药代动力学方法支持PD-1/PD-L1单抗治疗肿瘤患者的替代剂量方案选择指南》解读[J].
中国临床药理学与治疗学, 2022, 27(1): 86-94.
19. 唐慧敏，赵艳*，吴琼，刘维*. 靶控输注临床常用浓度舒芬太尼的效能：前瞻性随机对照研究. 中国微创外科杂志. 2021, 21(8): 705-709.
20. 杨平，周薇，张现化，周从亚，杨丽，刘维*. LC-MS/MS法检测儿童患者血浆中的西替利嗪浓度. 中国临床药理学杂志. 2021，37（22）：3161-3164.
21. 万伟，沈皓，王志妍，石伟龙，周应群，刘维*. 培门冬酶治疗恶性血液系统疾病的药物不良反应及处置措施研究. 中国临床药理学杂志, 2020, 36(1): 85-87.
22. 刘维，陈恳，田磊，胡凯，克晓燕，杨丽. 血液肿瘤专科美国临床药学高级实践带教基地与培养模式的建设。临床药物治疗杂志. 2019, 17(2): 88-92.
|
